161 related articles for article (PubMed ID: 25582574)
1. Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.
Arimany-Nardi C; Montraveta A; Lee-Vergés E; Puente XS; Koepsell H; Campo E; Colomer D; Pastor-Anglada M
Pharmacogenomics J; 2015 Aug; 15(4):363-71. PubMed ID: 25582574
[TBL] [Abstract][Full Text] [Related]
2. The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2.
Jouan E; Le Vee M; Denizot C; Da Violante G; Fardel O
Fundam Clin Pharmacol; 2014 Feb; 28(1):65-77. PubMed ID: 22913740
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
4. Esters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma Cells.
Huber S; Huettner JP; Hacker K; Bernhardt G; König J; Buschauer A
PLoS One; 2015; 10(7):e0133743. PubMed ID: 26196503
[TBL] [Abstract][Full Text] [Related]
5. Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake.
Hagos Y; Hundertmark P; Shnitsar V; Marada VV; Wulf G; Burckhardt G
Am J Physiol Renal Physiol; 2015 Feb; 308(4):F330-8. PubMed ID: 25477469
[TBL] [Abstract][Full Text] [Related]
6. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
7. Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2.
Kimura N; Masuda S; Katsura T; Inui K
Biochem Pharmacol; 2009 Apr; 77(8):1429-36. PubMed ID: 19426682
[TBL] [Abstract][Full Text] [Related]
8. Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs.
Marada VV; Flörl S; Kühne A; Müller J; Burckhardt G; Hagos Y
Pharmacol Res; 2015 Jan; 91():78-87. PubMed ID: 25481222
[TBL] [Abstract][Full Text] [Related]
9. Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter.
Angenoorth TJF; Stankovic S; Niello M; Holy M; Brandt SD; Sitte HH; Maier J
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884800
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the human organic cation transporter hOCT1.
Ciarimboli G; Struwe K; Arndt P; Gorboulev V; Koepsell H; Schlatter E; Hirsch JR
J Cell Physiol; 2004 Dec; 201(3):420-8. PubMed ID: 15389554
[TBL] [Abstract][Full Text] [Related]
11. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3.
Hayer-Zillgen M; Brüss M; Bönisch H
Br J Pharmacol; 2002 Jul; 136(6):829-36. PubMed ID: 12110607
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
Zhang L; Schaner ME; Giacomini KM
J Pharmacol Exp Ther; 1998 Jul; 286(1):354-61. PubMed ID: 9655880
[TBL] [Abstract][Full Text] [Related]
13. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.
Arimany-Nardi C; Koepsell H; Pastor-Anglada M
Pharmacogenomics J; 2015 Dec; 15(6):473-87. PubMed ID: 26526073
[TBL] [Abstract][Full Text] [Related]
14. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).
Bourdet DL; Pritchard JB; Thakker DR
J Pharmacol Exp Ther; 2005 Dec; 315(3):1288-97. PubMed ID: 16141367
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
Hendrickx R; Johansson JG; Lohmann C; Jenvert RM; Blomgren A; Börjesson L; Gustavsson L
J Med Chem; 2013 Sep; 56(18):7232-42. PubMed ID: 23984907
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
17. Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.
Nardinelli L; Sanabani SS; Didone A; Ferreira Pde B; Serpa M; Novaes MM; Marchiani M; Ruiz AL; Lima IS; Chamone Dde A; Bendit I
Acta Haematol; 2012; 127(4):228-34. PubMed ID: 22508387
[TBL] [Abstract][Full Text] [Related]
18. Interaction of six protoberberine alkaloids with human organic cation transporters 1, 2 and 3.
Li L; Sun S; Weng Y; Song F; Zhou S; Bai M; Zhou H; Zeng S; Jiang H
Xenobiotica; 2016; 46(2):175-83. PubMed ID: 26134304
[TBL] [Abstract][Full Text] [Related]
19. Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity.
Tu M; Sun S; Wang K; Peng X; Wang R; Li L; Zeng S; Zhou H; Jiang H
Toxicology; 2013 Sep; 311(3):225-30. PubMed ID: 23831208
[TBL] [Abstract][Full Text] [Related]
20. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
